BenevolentAI
Fleur Wood is an experienced professional in investor relations and strategic communications within the life sciences and healthcare sectors. Currently serving as Head of Investor Relations and VP at BenevolentAI since March 2022, Fleur previously held roles including Client Director at Radnor Capital Partners and Director at Bathwood Advisory, where ownership involved an integrated consultancy focused on investor relations. Significant prior experience includes executive leadership at hVIVO, consultancy for Shield Therapeutics, and director-level positions at Vectura Group and Computershare. Additionally, Fleur has a foundational background at Lehman Brothers in investor relations services.
This person is not in any teams
This person is not in any offices
BenevolentAI
8 followers
BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, discovering a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.